Cardiac Markers Market Is Expected To Reach US$ 5,079.5 Mn By 2026

The latest market report published by Acute Market Reports, Inc. “Cardiac Markers Market – Growth, Future Prospects, Competitive Analysis, 2018 – 2026,” the global market for cardiac markers was valued at US$ 2,515.8 million in 2017 and is expected to reach US$ 5,079.5 million by 2026, increasing to CAGR by 8.0 per cent from 2018 to 2026.

Market Insights

Cardiovascular diseases (CVDs) are considered to be among the leading causes of death worldwide, with an estimated 30% of global deaths due to CVDs. The first diagnosis of cardiac markers was made in the early 1950s and 1960s, when creatine kinase, lactate dehydrogenase or aspartate aminotransferase activities were analyzed to diagnose acute myocardial infringement. However, their low specificity and sensitivity have been a major challenge for their entry into the market. The 1980s saw a significant leap in the field of cardiac markers, with the introduction of the first monoclonal antibodies.

Browse Full Report Originally Published by Acute Market Reports at https://www.acutemarketreports.com/report/cardiac-markers-market

Since then, novel cardiac markers are being introduced in the market. Enzymatic assays and myoglobin assays have been eventually replaced by cardiac troponin I & T. Furthermore, their high sensitivity versions are becoming the need of the hour in acute myocardial infraction diagnostics. Simultaneously, markers for diagnosis of heart failure are also being adopted in routine use in several clinical laboratories. In recent years, more emphasis is being put on the development of cardiac markers that can be used for prevention and risk assessment of cardiovascular diseases.

The global cardiac markers market is expected to witness steady growth during the forecast period. Rapidly changing lifestyle patterns, widespread incorporation of unhealthy dietary habits, and increasing prevalence of cardiovascular diseases are the key factors driving the growth of the cardiac markers market. Furthermore, the proliferation of healthcare infrastructure in the Asia Pacific region, along with the growing emphasis on risk assessment of cardiac events will open new growth opportunities for the existing players and new market entrants. At present, cardiac troponin tests are considered as the gold standard biomarker for the detection of myocardial infarction. The new generation of the high-sensitivity cardiac troponin I assay is also helpful in determining long-term risk assessment of various patient groups that includes patients with stable coronary artery disease and heart failure.

Additionally, it is estimated that the demand for cardiac markers will be the highest in point-of-care settings. The high rate of emergency admission of patients with chest pain, and significant technological development in marker assays in terms of diagnosis specificity are the key factors supporting the dominance of the point-of-care segment. Cardiac troponin I & T-tests have the highest consumption in the point-of-care segment, while also having prominent usage in laboratory settings. Based on product types, reagents and kits occupy the largest revenue share in the global cardiac markers market. The high consumption rate of these products, along with bulk purchases are the prime attributes of this segment. On the other hand, the demand for analyzer instruments will be the highest in emerging markets of the Asia Pacific and Latin America. As the healthcare infrastructure in these regions is set to develop the demand for new technologically advanced analyzer instruments is also expected to grow correspondingly.

Geographically, North America and the Asia Pacific are the most prominent regional markets to watch on the global front. At present, the North America market captures the largest revenue share while the Asia Pacific region is expected to grow at the fastest CAGR during the forecast period. The dominance of the North American market is mainly attributed to high awareness, a significantly large patient pool suffering from chronic heart diseases, swift uptake of novel diagnostic tools, and better reimbursements. The growth of the Asia Pacific market will be mainly driven by the consistent development of healthcare infrastructure in India and China, significantly large population pool housing even large potential patient base, and growing healthcare infrastructure. Additionally, as the medical tourism market in the region is rapidly growing, the demand for advanced cardiac diagnostic tools is also set to rise in tow.

Based on the competitive landscape, the global cardiac markers market is characterized by the presence of a multitude of market players.

Key Market Movements:

• Consistent growth in the prevalence of chronic heart diseases, particularly in the geriatric population
• The growing contribution of cardiac diseases in total mortality
• Increasing demand for cardiac markers in emergency settings and point-of-care applications
• The increasing rate of the general population following sedentary lifestyle and unhealthy dietary habits, along with expensive consumption of alcohol and smoking
• Growing influx of advanced diagnostic assays and analyzers with evolved specificity
• The entry of major market players in the emerging regions and the Asia Pacific and Middle East & Africa

List of Companies Covered:

• Abbott Laboratories, Inc.
• Roche Diagnostics Limited
• Danaher Corporation
• Bio-Rad Laboratories, Inc.
• Becton, Dickinson, and Company
• LSI Medience Corporation
• Beckman Coulter, Inc. (Danaher Corporation)
• bioMerieux SA
• Ortho Clinical Diagnostics
• Siemens Healthcare Diagnostics
• Randox Laboratories Ltd.
• Tosoh Bioscience
• Quest Diagnostics, Inc.

Market Segmentation:

By Type

 • Cardiac Troponin I and T

 • CK-MB

 • Myoglobin

 • B type natriuretic peptide (BNP) and NT-proBNP

 • hs-C-Reactive Protein (hs-CRP)

 • Myeloperoxidase (MPD)

 • Ischaemia Modified Albumin

 • Others

 By-Products Type

 • Instruments

 • Chemiluminescence

 • Immunofluorescence

 • Immunochromatography

 • ELISA

 • Reagents and Kits

 By Condition Type

 • Plaque Formation

 • Plaque Instability/ Rupture

 • Myocardial Necrosis and Ischemia

 • Heart Failure

 By Testing Type

 • Laboratory Testing

 • Point-of-Care Testing

By Geography Segment Type

• North America (the U.S., Rest of North America)
• Europe (U.K., Germany, France, Rest of Europe)
• Asia Pacific (China, Japan, India, Rest of Asia Pacific)
• Rest of the World (the Middle East & Africa, Latin America)